This is a non-core endpoint: only basic statistics are computed.
See these related core endpoints for full statistics:
Use of pergolide
PDMED_PERGOLIDE
No definition available.
Endpoint definition
↥Report an error or suggest an improvement for this endpoint codes
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
557745 |
1. Apply sex-specific ruleNone |
557745 |
2. Check conditionsNone |
557745 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
1 out of 7 registries used, show all original rules. |
102 |
4. Check minimum number of events
Min. number of events
3
|
102 |
5. Include endpointsNone |
102 |
6. Filter based on genotype QC (FinnGen only) |
88 |
Control definitions (FinnGen only)
Controls for this endpoint are individuals that are not cases.
Extra metadata
- First used in FinnGen datafreeze
- DF2
Similar endpoints
↥List of similar endpoints to
Use of pergolide
based on the number of shared cases.
Similar with more cases:
- Neurological diseases
- Neurological diseases, wide definition
- Any prescribed medicine buy
- Any event in hilmo or specialist outpatient
Similar with less cases:
None
Case counts by codes
↥Summary Statistics
↥-FinRegistry-
This endpoint is excluded from FinRegistry analyses (omitted endpoint).
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 88 | 30 | 58 |
| Unadjusted period prevalence (%) | 0.02 | 0.01 | 0.03 |
| Median age at first event (years) | 61.12 | 57.05 | 63.23 |
-FinnGen-
Age distribution of first events
-FinnGen-
Year distribution of first events
-FinnGen-
Cumulative Incidence Function
Not a core endpoint, no data to show.
CodeWAS
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 89
- Matched controls
- 890
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
N04BC02
ATC
pergolide; oral
+∞
126.2
89
*
110
Kela drug reimbursment
Parkinson's disease and comparable movement disrorders
895.9
97.8
83
13
G20
ICD-10 Finland
Parkinson disease
666.4
93.5
80
11
N04BA02
ATC
levodopa and decarboxylase inhibitor; oral
582.0
92.4
83
20
N04BD01
ATC
selegiline; oral
519.2
83.1
72
7
N04BC05
ATC
pramipexole; oral
40.8
73.0
60
43
N04BX02
ATC
entacapone; oral
527.3
54.6
49
*
N04BA03
ATC
levodopa, decarboxylase inhibitor and COMT inhibitor; oral
338.9
52.1
48
*
N04BB01
ATC
amantadine; oral
113.1
33.9
35
5
F02.39*G20
ICD-10 Finland
Dementia in Parkinson's disease without information on additional symptoms
211.6
29.6
29
*
N04BD02
ATC
rasagiline; oral
381.3
28.5
27
*
193
Kela drug reimbursment
Rasagiline
323.6
25.0
24
*
N04BC04
ATC
ropinirole; oral
114.0
24.1
25
*
N87
ICPC
Parkinsonism
85.5
23.3
25
*
3320A
ICD-9 Finland
Parkinson's disease, Paralysis agitans
254.3
20.5
20
*
G02CB01
ATC
bromocriptine; systemic
119.2
18.3
19
*
N03AE01
ATC
clonazepam; systemic
17.8
15.9
25
19
N04BC06
ATC
cabergoline; oral
+∞
13.9
13
*
AAG20
NOMESCO Finland
Stereotactic intracranial implantation of electrodes
164.0
13.9
14
*
N04AA02
ATC
biperiden; systemic
38.4
13.1
16
5
N06DA03
ATC
rivastigmine; oral, transdermal
10.5
12.1
24
30
N05AH04
ATC
quetiapine; oral
5.2
10.9
28
72
N04BC01
ATC
bromocriptine; oral
+∞
10.6
10
*
AEA50
NOMESCO Finland
Adjustment of implanted neurostimulator
111.4
9.6
10
*
H02AA02
ATC
fludrocortisone; oral
21.4
9.2
13
7
A06AD11
ATC
lactulose; oral
4.0
9.2
39
145
N04BC09
ATC
rotigotine; transdermal
+∞
8.5
8
*
N04BX01
ATC
tolcapone; oral
+∞
8.5
8
*
307
Kela drug reimbursment
Tacrine, donepezil, rivastigmine, galantamine and other major and expensive drugs used to treat Alzheimer's disease
5.2
8.1
19
44
AEA00
NOMESCO Finland
Replacement of impulse generator of stimulation device in the nervous system
33.0
7.3
9
*
WYA30
NOMESCO Finland
Treatment of a patient needing special arrangements
6.5
6.4
16
29
N04AA01
ATC
trihexyphenidyl; oral
+∞
6.3
6
*
N04C02, ,
ATC
+∞
6.3
6
*
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
34
507
0.47
2.99
4.4
6.2
5.83
6.17
mmol/l
1.32
28
441
33
491
0.48
2.79
5.6
7.7
38.52
41.46
mmol/mol
1.92
28
440
34
492
0.50
2.53
20.6
19.6
80.91
68.35
ml/min/173m2
4.54
34
453
18
317
0.46
2.29
3.2
3.1
28.39
54.17
u/l
3.48
18
280
40
540
0.53
2.25
7.6
12.6
14.69
22.48
u/l
5.27
32
513
29
428
0.52
2.14
3.6
4.4
11.88
15.64
mm/h
0.92
24
373
0
52
0.00
1.96
0.0
3.7
—
1.22
—
0
42
8
170
0.42
1.70
2.4
3.1
23.00
32.00
u/l
—
8
160
41
527
0.59
1.65
22.0
19.5
27.89
27.54
mg/l
0.03
36
454
0
38
0.00
1.38
0.0
7.1
—
15.37
—
0
38
5
110
0.42
1.23
1.0
6.1
108.40
104.06
mmol/l
—
5
110
32
418
0.63
1.22
25.2
24.1
13.88
14.14
%
0.50
32
411
10
174
0.52
1.12
3.6
3.9
—
0.00
estimate
—
0
55
8
45
1.85
0.87
3.1
1.5
—
—
—
0
0
18
248
0.66
0.81
3.9
4.6
—
0.00
estimate
—
0
54
0
24
0.00
0.80
0.0
5.0
—
3.83
—
0
12
0
25
0.00
0.80
0.0
1.2
—
—
—
0
0
0
27
0.00
0.79
0.0
1.2
—
—
—
0
0
(3020427) Coagulation factor X inhibitor [Units/volume] in Platelet poor plasma by Coagulation assay
0
20
0.00
0.61
0.0
2.1
—
0.36
—
0
10
0
23
0.00
0.59
0.0
1.1
—
203.97
—
0
6
26
318
0.74
0.57
5.8
9.0
3.55
4.43
e9/l
2.43
21
270
18
232
0.72
0.55
2.4
3.2
111.89
128.47
ug/l
0.20
18
209
21
262
0.74
0.52
2.3
2.4
—
—
estimate
—
0
0
11
149
0.70
0.44
1.7
3.5
347.09
377.87
umol/l
0.47
11
122
0
15
0.00
0.41
0.0
1.2
—
—
—
0
0
0
15
0.00
0.41
0.0
1.2
—
—
—
0
0
0
15
0.00
0.41
0.0
1.3
—
—
—
0
0
0
17
0.00
0.41
0.0
1.2
—
—
—
0
0
0
17
0.00
0.41
0.0
1.4
—
—
—
0
0
0
18
0.00
0.40
0.0
1.3
—
—
—
0
0
0
18
0.00
0.40
0.0
1.6
—
—
—
0
0
0
18
0.00
0.40
0.0
1.3
—
—
—
0
0
0
19
0.00
0.39
0.0
1.4
—
—
—
0
0
0
19
0.00
0.39
0.0
1.3
—
—
—
0
0
18
144
1.31
0.39
2.0
2.0
—
—
—
0
0
10
80
1.28
0.21
5.3
9.8
—
—
—
0
0
0
11
0.00
0.21
0.0
1.2
—
—
—
0
0
0
11
0.00
0.21
0.0
1.3
—
—
—
0
0
0
11
0.00
0.21
0.0
1.2
—
—
—
0
0
0
12
0.00
0.21
0.0
1.3
—
—
—
0
0
0
12
0.00
0.21
0.0
1.3
—
—
—
0
0
0
14
0.00
0.20
0.0
1.5
—
—
—
0
0
11
126
0.86
0.12
3.0
1.8
—
—
—
0
0
8
93
0.85
0.07
3.5
1.8
—
—
—
0
0
20
189
1.08
0.05
3.2
3.8
0.43
0.60
e6/l
0.31
11
143
23
222
1.05
0.02
2.9
2.2
—
—
—
0
0
29
284
1.03
0.00
2.9
2.3
74.31
92.16
pmol/l
1.72
21
146
23
234
0.98
0.00
3.2
4.0
—
—
—
0
0
0
7
0.00
0.00
0.0
1.1
—
—
—
0
0
0
6
0.00
0.00
0.0
1.5
—
8.17
—
0
6
0
7
0.00
0.00
0.0
3.4
—
1.00
—
0
7
0
7
0.00
0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
0.00
0.0
1.2
—
—
—
0
0
0
6
0.00
0.00
0.0
1.3
—
—
—
0
0
0
7
0.00
0.00
0.0
4.1
—
155.57
—
0
7
0
7
0.00
0.00
0.0
2.1
—
20.91
—
0
7
0
7
0.00
0.00
0.0
1.3
—
—
—
0
0
0
7
0.00
0.00
0.0
1.3
—
—
—
0
0
0
7
0.00
0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
0.00
0.0
1.3
—
—
—
0
0
0
8
0.00
-0.00
0.0
2.0
—
14.75
—
0
8
0
8
0.00
-0.00
0.0
6.3
—
219.13
—
0
8
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.6
—
129.00
—
0
8
0
8
0.00
-0.00
0.0
1.4
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
5
49
1.02
-0.00
2.0
1.2
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.3
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.1
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.1
—
—
—
0
0
8
89
0.89
-0.00
3.5
1.8
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.4
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.4
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.3
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.3
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.2
—
—
—
0
0
Mortality – FinRegistry
↥This endpoint is excluded from FinRegistry analyses (omitted endpoint).
Relationships between endpoints
↥Index endpoint: PDMED_PERGOLIDE – Use of pergolide
GWS hits: -
This endpoint is excluded from FinRegistry analyses (omitted endpoint).